2 Beaten-Down Artificial Intelligence (AI) Stocks for Contrarian Investors to Consider Buying

The article is a bullish/contrarian commentary on Recursion Pharmaceuticals and Fiverr rather than new hard news. Recursion has no approved products or late-stage assets yet, but its AI-driven drug discovery platform and REC-4881 for FAP could provide upside if clinical progress continues. Fiverr is shifting toward higher-value complex projects, with EPS improving to $0.23 from $0.02, even as revenue and active buyers continue to decline.

Analysis

RXRX is still a validation story, not a business-model story. The key second-order issue is that big pharma’s AI adoption compresses Recursion’s moat: if the large-cap incumbents can internalize similar discovery workflows, RXRX must win on execution speed and translational success, not platform novelty. That makes the stock highly path-dependent on a handful of clinical readouts; in that setup, one positive signal can re-rate the equity materially, but a miss can erase years of narrative premium in a single quarter.

FVRR’s opportunity is more structural than cyclical. The move upmarket into larger, more complex projects should raise take-rate quality and reduce churn, but it also changes the competitive set: instead of competing with low-cost gig marketplaces, Fiverr increasingly competes with agencies, consultancies, and niche implementation shops. That is a better monetization path if the company can prove repeatability, but it also means slower sales cycles and a higher bar for trust, which can delay the revenue inflection even if unit economics improve.

The market may be underestimating the divergence between near-term optics and long-term survivability. For RXRX, sentiment can detach from fundamentals until a data catalyst arrives; for FVRR, margin improvement can mask underlying demand weakness for several quarters, so the stock can work even before topline turns if investors believe the new mix is durable. The contrarian edge is that both names are being priced as if their current headwinds are permanent, while the more realistic outcome is lumpy: one needs a clinical proof point, the other needs a buyer-behavior inflection.

Catalyst timing matters. RXRX likely trades in months-to-years around trial updates and any partnership validation, while FVRR can re-rate within 1-2 earnings cycles if spend-per-buyer and complex-project mix continue to improve. The main tail risk for both is narrative exhaustion: if progress is incremental rather than binary, multiple compression can persist despite seemingly positive operational trends.

Key Decisions for Investors

• RXRX: small starter long only, sized as a binary catalyst position into the next clinical update; target a 2-3x upside scenario on positive data, but cap risk tightly because a miss can justify another 30-50% drawdown.
• FVRR: initiate a modest long on post-earnings weakness if management confirms mix-shift toward higher-value projects; look for 12-18 month upside if spend-per-buyer and retention stabilize.
• Pair trade: long FVRR / short a basket of lower-quality freelance or SMB services exposure to express the view that upmarket platform monetization outperforms commoditized gig demand.
• For RXRX, avoid pre-catalyst size until there is evidence of clinical de-risking; alternatively use call spreads to define downside while keeping exposure to a data-driven rerating.
• Monitor both names through the lens of guidance quality rather than headline growth: if RXRX loses partnership or trial cadence, or if FVRR fails to halt active-buyer declines by the next 1-2 quarters, reduce aggressively.